2nd Quarter - Report

CONSUMER HEALTHCARE PRODUCTS ASSOCIATION for CONSUMER HEALTHCARE PRODUCTS ASSOCIATION

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Microbeads - H.R. 1321/S. 1424 - Microbead-Free Waters Act of 2015. Would prohibit the distribution of cosmetic products containing synthetic plastic microbeads after January 1, 2018; all sections.

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 1321 (114th), S. 1424 (114th)

Alcohol and Drug Abuse ALC

Dextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (re-introduction of Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644 in the 113th Congress, all sections).

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: Food & Drug Administration (FDA); Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 644 (114th), H.R. 3969 (114th)

Taxation/Internal Revenue Code TAX

Flexible spending arrangements (FSA) and health savings accounts (HSA) - H.R. 1270/S. 709 - Restoring Access to Medication Act. Repeals prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections.

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: SENATE; Food & Drug Administration (FDA); Treasury, Dept of; HOUSE OF REPRESENTATIVES

Bills named: S. 709 (114th), H.R. 1270 (114th)

Chemicals/Chemical Industry CHM

Toxic Substances Control Act of 1976 (P.L. 94-469) - H.R. 2576 - TSCA Modernization Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections. S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections.

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: Treasury, Dept of; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 697 (114th), H.R. 2576 (114th)

Food Industry (safety, labeling, etc.) FOO

Dietary Supplements - Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues."

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: SENATE; Treasury, Dept of; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives - S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections S. 1532 - Affordability is Access Act. Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.

LobbyistCovered position, as disclosed
JOHN GAY —
TRAVIS GIBBONS —
LINDSAY A MORRIS —

Contacted: SENATE; Treasury, Dept of; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 1438 (114th), S. 1532 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.